rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2017-576-579rsp-2443Research ArticleДИСКУССИИDISCUSSIONОтвет критикам «ТОЧНОСТИ»A RESPONSE TO «PRECISION» CRITICSКаратеевА. Е.KarateevA. E.
115522 Москва, Каширское шоссе, 34А
34A, Kashirskoe Shosse, Moscow 115522
aekarateev@rambler.ruФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation201727102017555576579Copyright © Каратеев А.Е., 20172017Каратеев А.Е.Karateev A.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2443
.
.
ReferencesFitzGerald GA. Imprecision: Limitations to interpretation of a large randomized clinical trial. Circulation. 2017;135(2):113-5. doi: 10.1161/CIRCULATIONAHA.116.026324FitzGerald GA. Imprecision: Limitations to interpretation of a large randomized clinical trial. Circulation. 2017;135(2):113-5. doi: 10.1161/CIRCULATIONAHA.116.026324Patrono C, Baigent C. Coxibs, traditional NSAIDs, and cardiovascular safety Post- PRECISION: What we thought we knew then and what we think we know now. Clin Pharmacol Ther. 2017;102(2):238-45. doi: 10.1002/cpt.696Patrono C, Baigent C. Coxibs, traditional NSAIDs, and cardiovascular safety Post- PRECISION: What we thought we knew then and what we think we know now. Clin Pharmacol Ther. 2017;102(2):238-45. doi: 10.1002/cpt.696Муравьев ЮВ. Почему исследование комплексной безопасности целекоксиба при артритах, названное РRECISION, является последним по счету, а не по значимости? Научно-практическая ревматология. 2017;55(3):324-6 [Muravyev YuV. Why is the study of the complex safety of celecoxib for arthritis, which is called PRECISION, last but not least? Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(3):324-6 (In Russ.). doi: 10.14412/1995-4484-2017-324-326Муравьев ЮВ. Почему исследование комплексной безопасности целекоксиба при артритах, названное РRECISION, является последним по счету, а не по значимости? Научно-практическая ревматология. 2017;55(3):324-6 [Muravyev YuV. Why is the study of the complex safety of celecoxib for arthritis, which is called PRECISION, last but not least? Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(3):324-6 (In Russ.). doi: 10.14412/1995-4484-2017-324-326Nissen S, Yeomans N, Solomon D, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016 Nov 13. doi: 10.1056/NEJMoa1611593Nissen S, Yeomans N, Solomon D, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016 Nov 13. doi: 10.1056/NEJMoa1611593Bertagnolli MM, Eagle CJ, Zauber AG, et al. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila). 2009 Apr;2(4):310-21. doi: 10.1158/1940-6207.CAPR-08-0206. Epub 2009 Mar 31.Bertagnolli MM, Eagle CJ, Zauber AG, et al. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila). 2009 Apr;2(4):310-21. doi: 10.1158/1940-6207.CAPR-08-0206. Epub 2009 Mar 31.Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006 Aug 31;355(9):885-95. doi: 10.1056/NEJMoa061652Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006 Aug 31;355(9):885-95. doi: 10.1056/NEJMoa061652Fabule J, Adebajo A. Comparative evaluation of cardiovascular outcomes in patients with osteoarthritis and rheumatoid arthritis on recommended doses of nonsteroidal anti- inflammatory drugs. Ther Adv Musculoskelet Dis. 2014 Aug;6(4):111-30. doi: 10.1177/1759720X14541668Fabule J, Adebajo A. Comparative evaluation of cardiovascular outcomes in patients with osteoarthritis and rheumatoid arthritis on recommended doses of nonsteroidal anti- inflammatory drugs. Ther Adv Musculoskelet Dis. 2014 Aug;6(4):111-30. doi: 10.1177/1759720X14541668Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000 Sep 13;284(10):1247-55. doi: 10.1001/jama.284.10.1247Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000 Sep 13;284(10):1247-55. doi: 10.1001/jama.284.10.1247Singh G, Fort JG, Goldstein JL, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med. 2006 Mar;119(3):255-66. doi: 10.1016/j.amjmed.2005.09.054Singh G, Fort JG, Goldstein JL, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med. 2006 Mar;119(3):255-66. doi: 10.1016/j.amjmed.2005.09.054Chan FK, Lanas A, Scheiman J, et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet. 2010 Jul 17;376(9736):173-9. doi: 10.1016/S0140-6736(10)60673-3. Epub 2010 Jun 16.Chan FK, Lanas A, Scheiman J, et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet. 2010 Jul 17;376(9736):173-9. doi: 10.1016/S0140-6736(10)60673-3. Epub 2010 Jun 16.Dahlberg LE, Holme I, Hoye K, Ringertz B. A randomized, multicentre, double-blind, parallel-group study to assess the adverse event-related discontinuation rate with celecoxib and diclofenac in elderly patients with osteoarthritis. Scand J Rheumatol. 2009 Mar- Apr;38(2):133-43. doi: 10.1080/03009740802419065Dahlberg LE, Holme I, Hoye K, Ringertz B. A randomized, multicentre, double-blind, parallel-group study to assess the adverse event-related discontinuation rate with celecoxib and diclofenac in elderly patients with osteoarthritis. Scand J Rheumatol. 2009 Mar- Apr;38(2):133-43. doi: 10.1080/03009740802419065Varas-Lorenzo С, Riera-Guardia N, Calingaert B, et al. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf. 2013;22:559-70. doi: 10.1002/pds.3437. Pub. online 25 April 2013 in Wiley Online Library (wileyonlinelibrary.com).Varas-Lorenzo С, Riera-Guardia N, Calingaert B, et al. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf. 2013;22:559-70. doi: 10.1002/pds.3437. Pub. online 25 April 2013 in Wiley Online Library (wileyonlinelibrary.com).Xu C, Gu K, Yasen Y, Hou Y. Efficacy and safety of celecoxib therapy in osteoarthritis: A meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016 May;95(20):e3585. doi: 10.1097/MD.0000000000003585Xu C, Gu K, Yasen Y, Hou Y. Efficacy and safety of celecoxib therapy in osteoarthritis: A meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016 May;95(20):e3585. doi: 10.1097/MD.0000000000003585Pincus T, Koch G, Lei H, et al. Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis. 2004 Aug;63(8):931-9. doi: 10.1136/ard.2003.020313. Epub 2004 Apr 13.Pincus T, Koch G, Lei H, et al. Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis. 2004 Aug;63(8):931-9. doi: 10.1136/ard.2003.020313. Epub 2004 Apr 13.Strand V, Simon LS, Dougados M, et al. Treatment of osteoarthritis with continuous versus intermittent celecoxib. J Rheumatol. 2011 Dec;38(12):2625-34. doi: 10.3899/jrheum.110636. Epub 2011 Nov 1.Strand V, Simon LS, Dougados M, et al. Treatment of osteoarthritis with continuous versus intermittent celecoxib. J Rheumatol. 2011 Dec;38(12):2625-34. doi: 10.3899/jrheum.110636. Epub 2011 Nov 1.Wanders A, van der Heijde D, Landewe R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005 Jun;52(6):1756-65. doi: 10.1002/art.21054Wanders A, van der Heijde D, Landewe R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005 Jun;52(6):1756-65. doi: 10.1002/art.21054Laine L, Kivitz A, Belo A, et al. Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers. Am J Gastroenterol. 2012;107:379-86. doi: 10.1038/ajg.2011.443Laine L, Kivitz A, Belo A, et al. Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers. Am J Gastroenterol. 2012;107:379-86. doi: 10.1038/ajg.2011.443Goldstein J, Hochberg M, Fort J, et al. Clinical trial: the incidence of NSAID-associated en-doscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole mag-nesium) vs. enteric-coated naproxen alone. Aliment Pharmacol Ther. 2010;32(3):401- 13. doi: 10.1111/j.1365-2036.2010.04378.xGoldstein J, Hochberg M, Fort J, et al. Clinical trial: the incidence of NSAID-associated en-doscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole mag-nesium) vs. enteric-coated naproxen alone. Aliment Pharmacol Ther. 2010;32(3):401- 13. doi: 10.1111/j.1365-2036.2010.04378.xTrelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti- inflammatory drugs: network meta-analysis. BMJ. 2011;342:7086. doi: 10.1136/bmj.c7086Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti- inflammatory drugs: network meta-analysis. BMJ. 2011;342:7086. doi: 10.1136/bmj.c7086McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011 Sep;8(9):e1001098. doi: 10.1371/journal.pmed.1001098. Epub 2011 Sep 27.McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011 Sep;8(9):e1001098. doi: 10.1371/journal.pmed.1001098. Epub 2011 Sep 27.Gunter BR, Butler KA, Wallace RL, et al. Non-steroidal antiinflammatory drug-induced cardiovascular adverse events: a metaanalysis. J Clin Pharm Ther. 2017 Feb;42(1):27-38. doi: 10.1111/jcpt.12484. Epub 2016 Dec 26.Gunter BR, Butler KA, Wallace RL, et al. Non-steroidal antiinflammatory drug-induced cardiovascular adverse events: a metaanalysis. J Clin Pharm Ther. 2017 Feb;42(1):27-38. doi: 10.1111/jcpt.12484. Epub 2016 Dec 26.
The authors declare that there are no conflicts of interest present.